In its quest to revolutionize the healthcare industry, AstraZeneca has unveiled a new health-tech venture called Evinova. The business aims to leverage its expertise in clinical trial design and study delivery, offering solutions on a larger scale to trial sponsors, clinical research organizations, care teams, and patients. This initiative is expected to speed up the development of new drugs, bring care closer to patients’ homes and ease the burden on healthcare systems.

To reach a broader audience and bring Evinova’s digital health solutions to market, AstraZeneca has formed major collaborations with Parexel and Fortrea. These partnerships will allow Evinova’s cutting-edge technologies to be made available to a wider customer base, supporting the company’s mission of improving patient care and driving healthcare transformation while reducing carbon emissions.

“Evinova represents a significant step forward in our mission to improve patient outcomes,” said Pascal Soriot, CEO of AstraZeneca. “With our deep scientific expertise combined with AI-enabled digital technologies at scale, we have an incredible opportunity to make a positive impact on the healthcare industry.”

For more information about Evinova and its collaboration partners, please contact Michael Susin at michael.susin@wsj.com.